Upon joining the study, you will be randomly assigned to receive either BGB-16673 or pirtobrutinib. Both medications are taken by mouth in the form of film-coated tablets.

The random assignment means that neither you nor your doctor can choose which medication you will receive. This is done to ensure the study results are reliable.

You will receive one of two medications, depending on your assigned group. Both are designed to treat your condition and are taken orally.

If assigned to the BGB-16673 group, you will take this medication according to the dosing schedule provided by your study doctor.

If assigned to the pirtobrutinib group (also known as Jaypirca), you will take 100 mg tablets according to the dosing schedule provided by your study doctor.

The specific dosage, frequency, and duration of treatment will be determined by your study doctor based on the study protocol and your individual response to the medication.

Throughout the study, you will undergo regular monitoring to evaluate how the treatment is working and to check for any side effects.

This will include imaging tests such as computed tomography (a type of scan that creates detailed pictures of the inside of your body) or magnetic resonance imaging (another type of scan that uses magnets and radio waves to create images).

Your doctor will assess whether your disease is responding to treatment, staying stable, or progressing. This assessment will be done by both your study doctor and an independent group of experts who review the results.

Blood tests and other laboratory tests will be performed regularly to monitor your overall health and detect any abnormalities.

You will be asked to complete questionnaires about your overall health, daily activities, physical functioning, and any symptoms you may be experiencing.

These questionnaires help evaluate how the treatment affects your quality of life, including your energy levels and ability to perform everyday tasks.

Your study doctor will closely monitor you for any side effects or adverse events that may occur during treatment.

Any side effects will be recorded and graded according to their severity using standardized criteria.

If you experience any side effects, your doctor may adjust your treatment or provide additional care as needed.

You will continue taking your assigned medication as long as it is benefiting you and you are not experiencing unacceptable side effects.

Your doctor will regularly evaluate whether the disease is responding to treatment or if it is progressing.

The duration of your participation in the study will depend on how well the treatment works for you and how well you tolerate it.

If you stop taking the study medication for any reason, you will enter a follow-up period.

During follow-up, your doctor will continue to monitor your health status and disease progression.

Information will be collected about any additional treatments you may receive for your condition after stopping the study medication.

The study is expected to continue until approximately November 2028, though your individual participation may be shorter or longer depending on your specific circumstances.